Answer
Diarrhoea is very common (at least 1 in 10) with intravenous Herceptin (trastuzumab), alone or combined with chemotherapy, with the frequency category based on the highest percentage seen in pivotal clinical trials.
Sources for this answer
- Herceptin 150mg Powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.8 Undesirable effects · Version 52Document updated
Sources checked